Donor lymphocyte infusion after allogeneic stem cell transplantation

Luca Castagna; Barbara Sarina; Stefania Bramanti; Paolo Perseghin; Jacopo Mariotti; Lucio Morabito

doi:10.1016/j.transci.2016.05.011

Donor lymphocyte infusion after allogeneic stem cell transplantation

Luca Castagna, Barbara Sarina, Stefania Bramanti, Paolo Perseghin, Jacopo Mariotti, Lucio Morabito

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.

Original language	English
Pages (from-to)	345-355
Number of pages	11
Journal	Transfusion and Apheresis Science
Volume	54
Issue number	3
DOIs	https://doi.org/10.1016/j.transci.2016.05.011
Publication status	Published - Jun 1 2016

Keywords

Allogeneic transplantation
DLI
Hematological disease
Pre-emeptive
Relapse

ASJC Scopus subject areas

Hematology

Access to Document

10.1016/j.transci.2016.05.011

Fingerprint Dive into the research topics of 'Donor lymphocyte infusion after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this

@article{de8b960342074925af7db2a560f959db,

title = "Donor lymphocyte infusion after allogeneic stem cell transplantation",

abstract = "Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.",

keywords = "Allogeneic transplantation, DLI, Hematological disease, Pre-emeptive, Relapse",

author = "Luca Castagna and Barbara Sarina and Stefania Bramanti and Paolo Perseghin and Jacopo Mariotti and Lucio Morabito",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.transci.2016.05.011",

language = "English",

volume = "54",

pages = "345--355",

journal = "Transfusion and Apheresis Science",

issn = "1473-0502",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - Donor lymphocyte infusion after allogeneic stem cell transplantation

AU - Castagna, Luca

AU - Sarina, Barbara

AU - Bramanti, Stefania

AU - Perseghin, Paolo

AU - Mariotti, Jacopo

AU - Morabito, Lucio

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.

AB - Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.

KW - Allogeneic transplantation

KW - DLI

KW - Hematological disease

KW - Pre-emeptive

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84969531842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969531842&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2016.05.011

DO - 10.1016/j.transci.2016.05.011

M3 - Article

AN - SCOPUS:84969531842

VL - 54

SP - 345

EP - 355

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -